Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum

Rhea-AI Summary

Atara Biotherapeutics (Nasdaq: ATRA) will participate in the Stifel Virtual Cell Therapy Forum, showcasing its innovative T-cell immunotherapy platform. Pascal Touchon, CEO, will present a fireside chat on July 9, 2024, at 6:45 a.m. PDT / 9:45 a.m. EDT. The discussion will be available via live webcast on the company's website, with a replay accessible for 30 days post-event. Atara leverages its allogeneic EBV T-cell platform to develop treatments for cancer and autoimmune diseases.

THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the Stifel Virtual Cell Therapy Forum on Tuesday, July 9, 2024 at 6:45 a.m. PDT / 9:45 a.m. EDT.

A live webcast of the presentation will be available by visiting the Investors and Media section of atarabio.com. An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.

About Atara Biotherapeutics, Inc.

Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in addition to next-generation AlloCAR-Ts designed for best-in-class opportunities across a broad range of hematological malignancies and B-cell driven autoimmune diseases. Atara is headquartered in Southern California. For more information, visit atarabio.com and follow @Atarabio on X and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240702299482/en/

Investor and Media Relations

Jason Awe, Ph.D.

Senior Director, Corporate Communications & Investor Relations

(805) 217-2287

jawe@atarabio.com

Source: Atara Biotherapeutics, Inc.

FAQ

When will Atara Biotherapeutics participate in the Stifel Virtual Cell Therapy Forum?

Atara Biotherapeutics will participate on July 9, 2024, at 6:45 a.m. PDT / 9:45 a.m. EDT.

How can I watch the Atara Biotherapeutics presentation at the Stifel Virtual Cell Therapy Forum?

You can watch the live webcast by visiting the Investors and Media section of atarabio.com.

Will there be a replay available for the Atara Biotherapeutics presentation at the Stifel Virtual Cell Therapy Forum?

Yes, an archived replay will be available on the company's website for 30 days following the live presentation.

What is the focus of Atara Biotherapeutics' platform?

Atara Biotherapeutics focuses on developing T-cell immunotherapies using its allogeneic Epstein-Barr virus (EBV) T-cell platform for cancer and autoimmune diseases.

Who will represent Atara Biotherapeutics at the Stifel Virtual Cell Therapy Forum?

Pascal Touchon, the President and CEO of Atara Biotherapeutics, will represent the company in a fireside chat.